CA3173758A1 - Preparation method and application of antibody drug conjugate - Google Patents

Preparation method and application of antibody drug conjugate

Info

Publication number
CA3173758A1
CA3173758A1 CA3173758A CA3173758A CA3173758A1 CA 3173758 A1 CA3173758 A1 CA 3173758A1 CA 3173758 A CA3173758 A CA 3173758A CA 3173758 A CA3173758 A CA 3173758A CA 3173758 A1 CA3173758 A1 CA 3173758A1
Authority
CA
Canada
Prior art keywords
optionally substituted
antibody
atoms
group
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173758A
Other languages
English (en)
Inventor
Hui Zhang
Xun Meng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Huilian Bio Pharm Co Ltd
Original Assignee
Shanghai Huilian Bio Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Huilian Bio Pharm Co Ltd filed Critical Shanghai Huilian Bio Pharm Co Ltd
Publication of CA3173758A1 publication Critical patent/CA3173758A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3173758A 2021-04-29 2022-04-28 Preparation method and application of antibody drug conjugate Pending CA3173758A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110475315 2021-04-29
CN202110475315.1 2021-04-29
PCT/CN2022/089724 WO2022228493A1 (zh) 2021-04-29 2022-04-28 抗体偶联药物的制备方法及应用

Publications (1)

Publication Number Publication Date
CA3173758A1 true CA3173758A1 (en) 2022-11-03

Family

ID=83846703

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3173758A Pending CA3173758A1 (en) 2021-04-29 2022-04-28 Preparation method and application of antibody drug conjugate
CA3173902A Pending CA3173902A1 (en) 2021-04-29 2022-04-28 Preparation method and application of antibody drug conjugate
CA3173511A Pending CA3173511A1 (en) 2021-04-29 2022-04-28 Preparation method and application of antibody drug conjugate

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3173902A Pending CA3173902A1 (en) 2021-04-29 2022-04-28 Preparation method and application of antibody drug conjugate
CA3173511A Pending CA3173511A1 (en) 2021-04-29 2022-04-28 Preparation method and application of antibody drug conjugate

Country Status (10)

Country Link
US (3) US20240238440A1 (cg-RX-API-DMAC10.html)
EP (3) EP4331612A4 (cg-RX-API-DMAC10.html)
JP (3) JP2024522389A (cg-RX-API-DMAC10.html)
KR (2) KR20240006029A (cg-RX-API-DMAC10.html)
CN (3) CN117241834A (cg-RX-API-DMAC10.html)
AU (1) AU2022263700A1 (cg-RX-API-DMAC10.html)
CA (3) CA3173758A1 (cg-RX-API-DMAC10.html)
IL (1) IL308025A (cg-RX-API-DMAC10.html)
TW (1) TW202308701A (cg-RX-API-DMAC10.html)
WO (3) WO2022228495A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024243085A3 (en) * 2023-05-19 2025-03-13 Solve Therapeutics, Inc. Drug-linkers and drug conjugates
WO2025222052A3 (en) * 2024-04-18 2025-12-04 Solve Therapeutics, Inc. Anti-ptk7 conjugates and uses thereof

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240238440A1 (en) * 2021-04-29 2024-07-18 Hyslink Therapeutics Preparation method for and application of antibody conjugated drug
CA3266848A1 (en) 2022-10-19 2024-04-25 Multitude Therapeutics Inc. Antibodies, antibody-drug conjugates, preparations and uses thereof
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
JP2026504840A (ja) * 2023-01-11 2026-02-10 ジェンマブ エー/エス リンカー、薬物リンカー、およびそれらの複合体、ならびにそれらを使用する方法
CN122080121A (zh) * 2023-03-22 2026-05-26 映恩生物科技(上海)有限公司 连接子及其在配体药物偶联物中的应用
TW202438069A (zh) * 2023-03-30 2024-10-01 大陸商上海齊魯製藥研究中心有限公司 依喜替康衍生物及其抗體藥物偶聯物
WO2024212922A1 (zh) * 2023-04-11 2024-10-17 映恩生物制药(苏州)有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
CN119300868B (zh) * 2023-05-11 2026-03-13 映恩生物科技(上海)有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
WO2024250984A1 (zh) * 2023-06-07 2024-12-12 上海维申医药有限公司 一种抗体药物偶联物,及其药物组合物、制备和用途
EP4737483A1 (en) * 2023-06-30 2026-05-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate production method including purification step using activated carbon material
WO2025011419A1 (zh) 2023-07-07 2025-01-16 上海诗健生物科技有限公司 一种连接子-药物分子及抗体药物偶联物、其制备方法和应用
IL326233A (en) * 2023-08-04 2026-03-01 Shanghai Huao Co Ltd Multidrug Linker and Antibody-Drug Conjugation
IL324001A (en) * 2023-09-22 2025-12-01 Obi Pharma Inc Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof
AU2024369355A1 (en) 2023-10-23 2026-05-07 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Camptothecin drug conjugate, and preparation method therefor and use thereof
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
WO2025149019A1 (en) * 2024-01-12 2025-07-17 Shanghai Ruotuo Biosciences Co., Ltd. Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025209545A1 (zh) * 2024-04-03 2025-10-09 上海药明合联生物技术有限公司 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof
WO2025261478A1 (en) * 2024-06-21 2025-12-26 Biotheus Inc. Antibody drug conjugates and applications thereof
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
WO2026037394A1 (zh) * 2024-08-16 2026-02-19 石药集团巨石生物制药有限公司 一种抗体药物偶联物及其用途
WO2026046186A1 (en) * 2024-08-27 2026-03-05 Suzhou Bioreinno Biotechnology Limited Company Linkers, linker conjugates and conjugate compounds thereof
WO2026067624A1 (zh) * 2024-09-27 2026-04-02 上海森辉医药有限公司 一种包含亲水基团的配体-药物偶联物及其在医药上的应用
CN119143876B (zh) * 2024-10-09 2025-09-16 武汉海沙百得生物技术有限公司 一种抗cd27l的全人源抗体或抗体片段及其应用
WO2026078443A1 (en) 2024-10-11 2026-04-16 Pheon Therapeutics Ltd. Antibody drug conjugates that bind cdcp1 and uses thereof
CN120484249B (zh) * 2025-04-29 2026-03-10 中山大学 一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
AU2002363658B2 (en) * 2001-11-14 2008-09-11 Rutgers, The State University Solubilized topoisomerase poisons
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
KR20210132742A (ko) * 2012-12-21 2021-11-04 알트루바이오 인코퍼레이티드 친수성 자기-희생 링커 및 그것의 포합체
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
GB2529356B (en) * 2013-04-28 2020-12-23 Genequantum Healthcare Co Ltd Novel linkers, coupling intermediates, conjugates, preparation method and application thereof
SG10201902571VA (en) * 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
EP3517114A1 (en) * 2014-04-29 2019-07-31 Genequantum Healthcare (Suzhou) Co., Ltd. New stable antibody-drug conjugate, preparation method and use thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
EP3347048B1 (en) 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
EP3700577A1 (en) 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
EP3790590A1 (en) 2018-05-10 2021-03-17 CIS Pharma AG Biocompatible copolymer containing multiple active agent molecules
CA3140063A1 (en) * 2019-05-20 2020-11-26 Novartis Ag Antibody drug conjugates having linkers comprising hydrophilic groups
CA3085001C (en) 2019-05-20 2021-10-05 Mabplex International, Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
US20240238440A1 (en) * 2021-04-29 2024-07-18 Hyslink Therapeutics Preparation method for and application of antibody conjugated drug
AU2022406708A1 (en) * 2021-12-10 2024-06-27 Multitude Therapeutics Inc. Anti-cdh6 antibodies and antibody-drug conjugates thereof
CA3266848A1 (en) * 2022-10-19 2024-04-25 Multitude Therapeutics Inc. Antibodies, antibody-drug conjugates, preparations and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024243085A3 (en) * 2023-05-19 2025-03-13 Solve Therapeutics, Inc. Drug-linkers and drug conjugates
WO2025222052A3 (en) * 2024-04-18 2025-12-04 Solve Therapeutics, Inc. Anti-ptk7 conjugates and uses thereof

Also Published As

Publication number Publication date
EP4331612A4 (en) 2026-06-03
US20240245795A1 (en) 2024-07-25
US20240238440A1 (en) 2024-07-18
AU2022263700A1 (en) 2023-11-16
EP4331613A4 (en) 2026-06-10
WO2022228495A1 (zh) 2022-11-03
WO2022228494A1 (zh) 2022-11-03
CA3173902A1 (en) 2022-11-03
EP4331612A1 (en) 2024-03-06
JP2024522389A (ja) 2024-06-19
US20240245799A1 (en) 2024-07-25
CA3173511A1 (en) 2023-10-28
EP4331611A4 (en) 2026-06-03
TW202309045A (zh) 2023-03-01
WO2022228493A1 (zh) 2022-11-03
JP2024522312A (ja) 2024-06-14
TW202308700A (zh) 2023-03-01
JP2024522388A (ja) 2024-06-19
KR20240006029A (ko) 2024-01-12
KR20240006028A (ko) 2024-01-12
CN117241833A (zh) 2023-12-15
IL308025A (en) 2023-12-01
EP4331613A1 (en) 2024-03-06
JP7900834B2 (ja) 2026-08-05
TW202308701A (zh) 2023-03-01
EP4331611A1 (en) 2024-03-06
CN117337195A (zh) 2024-01-02
CN117241834A (zh) 2023-12-15

Similar Documents

Publication Publication Date Title
EP4331611A1 (en) Preparation method and application of antibody drug conjugate
CA3021435C (en) Antibody drug conjugate linker
EP3756691A1 (en) Anti-cd123 antibodies and conjugates thereof
CA3090251A1 (en) Glypican 3 antibodies and conjugates thereof
TW202134284A (zh) 抗cd123抗體以及其結合物及衍生物
KR20240022626A (ko) 항종양 화합물 및이의 응용
CA3202759A1 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
KR20240150781A (ko) B7-h4 항체 약물 접합체를 포함하는 암 치료를 위한 병용요법
WO2025027554A1 (en) Humanized muc1 antibody and antibody drug conjugate
JP2026507705A (ja) 抗体薬物複合体、医薬組成物及びその使用
WO2025105486A1 (ja) 抗体-光感受性物質コンジュゲート
BR122020012304B1 (pt) Composto ligante para conjugados anticorpo-fármaco, método e intermediários de produção do mesmo

Legal Events

Date Code Title Description
P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240717

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240913

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240927

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250211

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250313

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250313

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250313

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250716

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251114

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260113

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260113

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260413

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260413